ECCMID 2018
AWG Member Company Participation at ECCMID 2018
Thirteen AWG member companies presented data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held April 21 – 24 in Madrid, Spain. Representatives from AWG member companies participated in 71 different oral sessions and poster presentations.
ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases.
Saturday, April 21st
Oral Abstract Session: MDR Gram-negatives: Clinical and Epidemiological Challenges
Time: 8:45 – 10:45 a.m. CET
Location: Hall R
Melinta Therapeutics:
8:57 – 9:07 a.m. CET
- #O0047 Predicting carbapenem resistance among Gram-negative pathogens in complicated urinary tract infections.
Paper Poster Session: Influenza and other Respiratory Viruses
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena
Arsanis, Inc.:
- #0021 Functional characterization of highly potent human monoclonal antibodies targeting different antigenic sites on the pre-fusion RSV-F protein
Paper Poster Session: Aspergillus in the Laboratory
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena
Cidara Therapeutics:
- #P0173 High and sustained lung epithelial lining fluid (ELF)-to-plasma exposure ratio from a single dose of rezafungin (CD101): efficacy comparison to posaconazole and micafungin in a mouse pulmonary aspergillosis infection model
SCYNEXIS, Inc.:
- #P0164 InVitro Activity of SCY-078, a Novel IV/Oral Glucan Synthase Inhibitor, against Aspergillusspp., Alone or in Combination with other Antifungal Therapies
- #P0165 Activity of SCY-078 and comparators against a collection of Aspergillus spp. including cryptic species and Cyp51A mutants
Paper Poster Session: Clinical trial experience – new antibacterial agents
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena
Melinta Therapeutics:
- #P0285 Meropenem-vaborbactam versus best-available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in patients with cancer.
Motif Bio Plc:
- #P0283 Potential cost savings opportunities with targeted iclaprim (ICL) compared to vancomycin (VAN) among hospitalized patients with acute bacterial skin and skin structure infectious due to potential avoidance of VAN-associated acute kidney injury
Nabriva Therapeutics:
- #P0276 Lefamulin Demonstrates Favorable Safety and Tolerability in Adults with Community-Acquired Bacterial Pneumonia (CABP) in the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
- #P0277 Lefamulin is Non-inferior to Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia (CABP): The Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
Paratek Pharmaceuticals:
- #P0271 Omadacycline gastrointestinal effects – an integrated safety analysis from the Phase 3 ABSSSI and CABP studies
- #P0272 Efficacy of omadacycline versus moxifloxacin in treating subjects from different geographic regions with community-acquired bacterial pneumonia (CABP)
- #P0273 Effects of oral omadacycline versus oral linezolid on lesion size and local signs of ABSSSI in the Phase 3 OASIS-2 study
- #P0274 Efficacy of oral omadacycline versus linezolid for treating adult subjects with ABSSSI: analysis by infection type and pathogen in the OASIS-2 study
- #P0275 Omadacycline versus moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP): efficacy analysis according to EMA requirements
Theravance Biopharma:
- #P0280 Clinical Experience with Telavancin for the Treatment of Elderly Patients (≥ 65 years): Preliminary Results from the Telavancin Observational Use Registry (TOUR)
- #P0279 Clinical Experience with Telavancin for the Treatment of Obese Patients (BMI > 30 kg/m2): Preliminary Results from the Telavancin Observational Use Registry (TOUR)
Paper Poster Session Activity of new or re-purposed non-beta-lactam drugs
against Gram-negatives
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena
Melinta Therapeutics:
- #P0094 Progress in the ESKAPE Pathogen Program: the in vitro profile of an advanced lead, RX-P2382
Paratek Pharmaceuticals:
- #P0102 Antimicrobial activity of omadacycline tested against clinical bacteria isolates collected from hospitals in China, including Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013-2016)
Paper Poster Session: Antibiotic toxicity: from mechanisms to clinical data
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena
Melinta Therapeutics:
- #P0151 Progress in the ESKAPE Pathogen Program: the exploratory in vivo toxicological profile of an advanced lead, RX-P2382
Paper Poster Session: Pre-clinical PK/PD
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena
Nabriva Therapeutics:
- #P0250 In Vitro Bactericidal Activity of Lefamulin against Streptococcus pneumoniae Isolates
- #P0257 Tissue Distribution of [14C]-Lefamulin in the Urogenital Tract in Rats
Paper Poster Session: Clostridium difficile – clinical news
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena
Nabriva Therapeutics:
- #P0387 Correlation of high-risk antibiotic use and hospital-associated C. difficile infections: data from 195 US hospitals
Oral Abstract Session: New drugs and tricks against MDR bacteria
Time: 4:30 – 6:30 p.m. CET
Location: Hall L
Melinta Therapeutics:
4:54 – 5:04 p.m. CET
- #O0248 Progress in the ESKAPE Pathogen Program: the in vivo profile of an advanced lead, RX-P2382.
Spero Therapeutics:
5:06 p.m. – 5:16 p.m. CET
- #O0249 Characterization of SPR741, a potentiating polymyxin B analog, using atomic force microscopy and chemical-genomics profiling
Sunday, April 22nd
Mini-Oral Flash Session: CMV – the challenge continues
Time: 11:30 a.m. – 12:30 p.m. CET
Location: Hall R
Melinta Therapeutics:
11:42 a.m. CET
- #O0422 Meropenem-vaborbactam versus best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in all treated patients regardless of pathogen
Mini-Oral Flash Sessions: Snapshot on pre-registration clinical trials
Time: 11:30 a.m. – 12:30 pm. CET
Location: Hall Q
Motif Bio Plc:
11:50 a.m. CET
- #O0424 A phase-3, randomized, double-blind, multicentre study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive bacteria (REVIVE-2)
Paratek Pharmaceuticals:
11:54 a.m. CET
- #O0425 A Phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study)
Paper Poster Session: The war of clones in Escherichia coli and Klebsiella
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena
Arsanis, Inc.:
- #0913 ST131-O25b is the dominant clone among Escherichia coli airway colonizers in mechanically ventilated patients: a prospective study
Paper Poster Session: Focus: S. pneumoniae
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena
Melinta Therapeutics:
- #P0599 In vitro evaluation of delafloxacin activity when tested against contemporary European community-acquired bacterial respiratory tract infection isolates (2014-2017): Results from the SENTRY Antimicrobial Surveillance Program
Paper Poster Session: Community-acquired respiratory infections
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena
Nabriva Therapeutics:
- #P0614 A multicentre evaluation of pathogen distribution in culture positive patients admitted with pneumonia in the US
- #P0619 In Vitro Activity of Lefamulin Against Bacterial Pathogens Collected From Patients with Community- or Hospital- Acquired Respiratory Tract Infections: 2016 SENTRY Data from Europe
Paper Poster Session: Typing of bacterial pathogens – methods, results, applications
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena
Arsanis, Inc.:
- #1006 Genotyping of Staphylococcus aureus links nasal carriage to lower airway colonization in mechanically ventilated patients
Paper Poster Session: Carbapenem plus carbapenemase inhibitor combinations: in
vitro and in vivo data
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena
Melinta Therapeutics:
- #P1043 Activity of Meropenem-Vaborbactam against Enterobacteriaceae Isolates Collected During 2016
Paper Poster Session: Update on Pneumocystis
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena
SCYNEXIS, Inc.
- #P1226 SCY-078 Demonstrates Antifungal Activity Against Pneumocystis in a Prophylactic Murine Model of Pneumocystis Pneumonia
Oral Abstract Session: Drug combinations: pre-clinical evidence
Time: 4:00 – 6:00 p.m. CET
Location: Hall L
ContraFect Corporation:
5:46 p.m. – 5:56 p.m. CET
- #O0581 Efficacy of lysin CF-301 in addition to daptomycin or vancomycin in a rabbit model of infective endocarditis due to methicillin-resistant Staph aureus (MRSA)
Mini-oral ePoster Sessions: Beta-lactamase inhibitors: from bench to bedside
Time: 4:00 – 5:00 p.m. CET
Location: ePoster Arena 3
Melinta Therapeutics:
- #O0608 Meropenem-vaborbactam versus best available therapy for infections due to carbapenem-resistant Enterobacteriaceae in TANGO II: impact of prior antibiotic failure on clinical outcomes
Monday, April 23rd
Mini-oral ePoster Sessions: Urinary tract infections: optimal management in the era of
MDR
Time: 11:30 a.m.- 12:30 p.m. CET
Location: Paper Poster Arena
Iterum Therapeutics:
11:36 a.m. CET
- #O0736 Impact of Initial Inappropriate Antibiotic Therapy on Outcome for Uncomplicated Urinary Tract Infection Due to Antibiotic Non-Susceptible Enterobacteriaceae
Paper Poster Session: Microbial virulence and pathogenesis
Time: 12:30 – 1:30 p.m. CET
Location: ePoster Arena 1
Arsanis, Inc.:
- #1403 Serum sensitivity of Klebsiella pneumoniae correlates with the O-serotype and determines the mechanisms required for mAb-based protection from infection
- #1409 Elucidation of the role of the complement system in killing Escherichia coli by using in vitro reconstituted complement pathways
Paper Poster Session: Biofilms I – Gram-positive pathogens
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena
ContraFect Corporation:
- #P1435 Translational study of the antibiofilm activity of lysin CF-301 in an infected hemodialysis catheter from patient with suspected Staph aureus bacteremia
Paper Poster Session: Resistance in various Gram-positives
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena
Motif Bio Plc:
- #P1838 Surveillance of iclaprim activity: in vitro susceptibility of Staphylococcus aureus resistant to clindamycin/tetracycline and beta-haemolytic streptococci resistant to macrolides/tetracyclines skin and skin-structure pathogens collected during 2015-2016 from Europe
Nabriva Therapeutics:
- #P1823 In Vitro Activity of Lefamulin against Contemporary Staphylococcus aureus Isolates from Patients in Europe (SENTRY 2016)
Paratek Pharmaceuticals:
- #P1821 In vitro activity of omadacycline against resistant Streptococcus pneumoniae and Haemophilus influenzae
- #P1822 Activity of omadacycline and comparators against Gram-positive and -negative clinical isolates (including resistant organism subsets) collected in 2017 from patients in European medical centres: SENTRY Surveillance Program Results
- #P1829 In vitro activity of omadacycline against resistant Staphylococcus aureus
Theravance Biopharma:
- #P1808 Activity of Telavancin Against a Global Collection of Multidrug-Resistant Gram-Positive Isolates and Ceftaroline Nonsusceptible Staphylococcus aureus (2015-2017)
Paper Poster Session: Exploring antibacterial activity with the help of
pharmacology
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena
Iterum Therapeutics:
- #P1527 Antimicrobial Activity of Sulopenem in the Urine of Healthy Volunteers
Paper Poster Session: Seeking synergy in drug combinations
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena
Spero Therapeutics:
- #P1671 Antimicrobial activity of Ceftazidime and Piperacillin-Tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary-tract infections
- #P1672 Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of beta-lactam agents against a challenge set of Gram-negative pathogens
- #P1673 In vitro activity of ceftazidime alone and in combination with SPR741 against anaerobic bacteria
- #P1674 Bactericidal activity of ceftazidime in combination with SPR741 against susceptible, extended-spectrum beta-lactamase producing, and multi-drug resistant Escherichia coli, Klebsiella pneumoniae, and Enterobacter species
- #P1675 Bactericidal activity of piperacillin-tazobactam in combination with SPR741 against susceptible, extended-spectrum beta-lactamase producing, and multi-drug resistant Escherichia coli, Klebsiella pneumoniae, and Enterobacter species
Mini-oral ePoster Session: Hot topics in antifungal use
Time: 2:30 – 3:30 p.m. CET
Location: ePoster Arena 1
Amplyx Pharmaceuticals:
2:54 p.m. CET
- #O0796 Candida auris is highly in vitro susceptible to APX001A in EUCAST antifungal susceptibility testing
3:00 p.m. CET
- #O0797 Pharmacokinetics/pharmacodynamics (PK/PD) of the novel, first-in-class glycosylphosphatidylinositol (GPI) inhibitor APX001 in the neutropenic murine invasive candidiasis model against C. albicans (CA), C. glabrata (CG), and C. auris (CAU)
Tuesday, April 24th
Oral Abstract Session: News in Antifungal Therapy
Time: 9:00-11:00 a.m. CET
Location: Hall K
Cidara Therapeutics:
9:22 – 9:32 a.m. CET
- #O0938 Multicentre determination of CD101 (rezafungin) susceptibility of Candida species by the EUCAST method
9:34 – 9:44 a.m. CET
- #O0939 Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant A. fumigatus isolates and cryptic species
10:10 – 10:20 a.m. CET
- #O0942 EUCAST susceptibility testing of rezafungin (CD101): activity against Candida auris
10:34 – 10:44 a.m. CET
- #O0944 Pharmacodynamic (PD) evaluation of rezafungin against Candida auris in the persistently neutropenic murine model of disseminated candidiasis
Amplyx Pharmaceuticals:
9:58 – 10:08 a.m. CET
- #O0941 APX001 is effective against echinocandin and multi-drug resistant Candida isolates
10:43 – 10:53 a.m. CET
- #O0943 Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model
Paper Poster Session: Phages and therapeutic antibodies
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena
ContraFect Corporation:
- #P2450 European surveillance study of CF-301 activity against contemporary Staph aureus isolates from Italy, Greece, and Hungary
- #P2451 Optimal timing of the Co-administration of lysin CF-301 with daptomycin in a rabbit model of infective endocarditis due to MRSA
- #P2452 Lysin CF-301 exhibits a low propensity for decreased susceptibility and prevents daptomycin resistance in a rabbit model of Staph aureus infective endocarditis
Paper Poster Session: Clinical pharmacokinetics
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena
Melinta Therapeutics:
- P2205 Ex vivo characterization of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem-vaborbactam
Spero Therapeutics:
- #P2206 Safety of SPR741, a novel polymyxin potentiator, in healthy adults receiving single- and multiple-dose intravenous administrations
- #P2233 Determination of the pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SPR741 in healthy volunteers
Paper Poster Session: Skin and soft-tissue infections: risk factors and management
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena
Melinta Therapeutics:
- #P2112 A multicentre evaluation of pathogen distribution in culture-positive patients admitted with skin and skin-structure infection in the US.
Paper Poster Session: Urinary tract infection – risks, diagnosis, treatment
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena
Iterum Therapeutics:
- #P2147 Impact of ESBL-Positivity and Quinolone Non-Susceptibility on Outcome for Inpatients with Complicated Urinary Tract Infections: A Multicenter Evaluation in the US.
Oral Abstract Session: Innovations in molecular pathogen detection
Time: 1:30 – 3:30 p.m. CET
Location: Hall C
T2 Biosystems:
2:42 p.m. CET
- #O1092 Comparative clinical evaluation of the T2Bacteria Panel versus blood culture for the diagnosis of bacteremia
ePoster Viewing
Satuday, April 21st – Tuesday, April 24th
Time: 8:00 a.m. – 6:00 p.m. CET
Various bacterial infections:
Melinta Therapeutics:
- #E0285 Demographics of culture positive patients in the admission period with skin and skin structure infection in the US: a multicenter evaluation of pathogen distribution.
Motif Bio Plc:
- #E0283 Frequency of vancomycin-associated acute kidney injury and healthcare utilization among Veterans’ Affairs patients with skin and skin structure infections
- http://www.eccmidlive.org/#resources/frequency-of-vancomycin-associated-acute-kidney-injury-and-healthcare-utilization-among-veterans-affairs-patients-with-skin-and-skin-structure-infections